

**PCR-/NAT *Helicobacter pylori***  
**(RV 533) Mai / Juni 2019**



**Tabelle 1: Probenzusammensetzung und erwartetes Ergebnis.**  
*Sample composition and expected results.*

	<i>Erwartet / expected</i>		<i>Probenzusammensetzung / Sample composition</i>
1915331	+++	61/71	<i>Helicobacter pylori</i> (~ 5x10 <sup>5</sup> CFU/mL) Clarithromycin resistant (GGA mut. in 23S rDNA)
1915332	∅	62	<i>Escherichia coli</i> K12
1915333	++	61/71	<i>Helicobacter pylori</i> (~ 5x10 <sup>4</sup> CFU/mL) Clarithromycin resistant (GGA mut. in 23S rDNA)
1915334	∅	62	<i>Helicobacter mustelae</i> (~ 5x10 <sup>4</sup> CFU/mL)

**Tabelle 2: Häufigkeit der Mitteilung verschiedener Befunde.**  
*Absolute numbers of reported individual results.*

<i>n = 52</i>	<i>Probennummer (Sample no.)</i>				<i>Inhibition</i>				
	1915331	1915332	1915333	1915334	1915331	1915332	1915333	1915334	
<b>Befund</b> <i>Result</i>									
<b>Positiv</b>	52 <sup>1)</sup>	1	52 <sup>1)</sup>	7	n.d.	1	1	1	1
<b>Negativ</b>	0	51	0	45	nein <i>no</i>	51	51	51	51
<b>Fraglich</b> <i>Questionable</i>	0	0	0	0	ja <i>yes</i>	0	0	0	0

**Tabelle 3: Häufigkeit richtig positiver und richtig negativer NAT-Befunde bei Anwendern verschiedener Methoden.**  
*Absolute numbers and relative frequency of reported true positive and true negative results among various NAT methods.*

<b>NAT-Methode</b> [Code] (total number *)	<b>NAT richtig positiv</b> <i>True positive results</i>			<b>NAT richtig negativ</b> <i>True negative results</i>		
	<b>Absolut</b> <i>Absolute</i>	<b>Relativ</b> <i>Relative</i>	<b>%</b>	<b>Absolut</b> <i>Absolute</i>	<b>Relativ</b> <i>Relative</i>	<b>%</b>
Hain GenoType Helico [20] (n = 22)	44	44 / 44	100	44	44 / 44	100
Ingenetix ClariRes [21] (n = 2)	4	4 / 4	100	4	4 / 4	100
r-Biopharm RIDAGENE [22] (n = 5)	10	10 / 10	100	10	10 / 10	100
Commercial assay [27] (n = 10)	20	20 / 20	100	16	16 / 20	80
<i>In house</i> PCR assay [28] (n = 18)	36	36 / 36	100	32	32 / 36	89

\* Durch Mehrfachnennung oder fehlende Angabe kann die absolute Zahl der Ergebnisse (Tab. 2) von der Anzahl der Teilnehmer abweichen.  
 Due to reporting results of multiple assay systems or missing specifications, the effective numbers are not correlating with the number of participants

**Comments:** <sup>1)</sup> Forty-five of the 52 participants reported results for molecular Clarithromycin-susceptibility testing. All reported results were correct.